Estrella Immunopharma Inc (ESLA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 1,927 | 1,384 | 1,627 | 1,317 | 422 |
| TOTAL | $2,157 | $1,677 | $2,024 | $1,481 | $944 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 1,500 | 1,500 | 1,500 | 1,500 | 1,500 |
| TOTAL | $1,500 | $1,500 | $1,500 | $1,500 | $1,500 |
| Total Assets | $3,657 | $3,177 | $3,524 | $2,981 | $2,444 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 194 | 793 | 81 | 119 | 132 |
| Accrued Expenses | 8,268 | 12,393 | 12,893 | 8,768 | 4,143 |
| Other current liabilities | 465 | 357 | 385 | 188 | N/A |
| TOTAL | $8,928 | $13,543 | $13,360 | $9,075 | $4,275 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $8,928 | $13,543 | $13,360 | $9,075 | $4,275 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 43,034 | 42,665 | 37,766 | 37,066 | 36,166 |
| Common Shares | 4 | 4 | 4 | 4 | 4 |
| Retained earnings | -39,283 | -36,991 | -36,378 | -31,577 | -26,032 |
| Other shareholders' equity | 402 | 402 | 402 | 402 | 402 |
| TOTAL | $-5,270 | $-10,366 | $-9,836 | $-6,095 | $-1,831 |
| Total Liabilities And Equity | $3,657 | $3,177 | $3,524 | $2,981 | $2,444 |